Understanding muscle loss in chronic kidney disease patients
Risk Factors of Chronic Kidney Disease-related Sarcopenia and Its Relationship With Poor Prognosis
Nanfang Hospital, Southern Medical University · NCT05353660
This study looks at how chronic kidney disease affects muscle loss in patients, especially those with low kidney function or on dialysis, to better understand this serious issue.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University (other) |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05353660 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the relationship between chronic kidney disease (CKD) and sarcopenia, a condition characterized by the loss of muscle mass and function. It aims to identify the prevalence and contributing factors of sarcopenia in CKD patients, particularly those with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m² or those on maintenance dialysis. By analyzing the impact of uremic toxins, inflammation, and other factors on muscle health, the study seeks to enhance understanding of this serious complication in CKD. No interventions will be administered, as the study is observational in nature.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 80 with chronic kidney disease and an eGFR below 60 ml/min/1.73m² or those receiving maintenance dialysis.
Not a fit: Patients with neuromuscular or neurodegenerative diseases, advanced malignancies, or serious cardiovascular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for sarcopenia in CKD patients, potentially enhancing their quality of life.
How similar studies have performed: While the relationship between CKD and sarcopenia has been noted in previous studies, this specific observational approach is less common and may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1.aged ≥18 years and \<80 years 2.eGFR\<60ml/min/1.73m2 or had received maintenance dialysis for at least 3 months. Exclusion Criteria: * 1.Patients with neuromuscular diseases: such as muscular dystrophy, amyotrophic lateral sclerosis, spinal cord injury, stroke, and myasthenia gravis; 2.Patients with neurodegenerative diseases: such as Alzheimer's disease, Parkinson's disease and Huntington's disease; 3.patients with advanced malignant tumors; 4.Patients with acute infectious diseases in the past 3 months; 5. Patients with serious cardiovascular or cerebrovascular disease; 6.Moderate to severe edema; 7.Patients with rheumatoid arthritis, multiple sclerosis, or acute gout that limit joint mobility; 8.Pregnant ; 9.Patients identified to be unsuitable for enrollment by the study physician
Where this trial is running
Guangzhou, Guangdong
- Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Study coordinator: Min Liang, MD
- Email: nfyylm@163.com
- Phone: +86-20-61686217
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Kidney Diseases, Sarcopenia